Crispr Therapeutics granted orphan status for follicular lymphoma treatment
The FDA granted Crispr Therapeutics (CRSP) orphan status for its treatment of follicular lymphoma.Don't Miss Our End of Quarter Offers: ...
Medindia3d
VARIANT Receives Positive Feedback from the European Medicines Agency (EMA) for its Innovative Gene Replacement Therapy, VAR002
Variant, a company dedicated to developing innovative treatments for orphan inherited eye diseases, and the Rare Ocular Diseases Center at the University ofCampania Luigi Vanvitelli ...
Pharmaceutical Technology4d
Atsena closes $150m in Series C round to progress gene therapy
Atsena Therapeutics has completed an oversubscribed Series C financing round, raising $150m to support the advancement of ...
MyChesCo on MSN5d
AscellaHealth Launches Specialty & Rare Pipeline Digest to Guide Pharmaceutical Stakeholders
AscellaHealth has introduced its latest Specialty & Rare Pipeline Digest™, a quarterly publication designed to provide ...
PANTHERx® Rare Introduces New Capabilities to Support Cell and Gene Therapies
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...
Opus Genetics to Participate in Upcoming Investor Conference in April
Company management will be available for one-on-one meetings during the conference. If you are interested in arranging a meeting, please contact your conference representative or send an email to ...
Fierce Biotech5d
Atsena raises $150M for ocular gene therapies with Bain, Sofinnova in tow
The $150 million will also go toward Atsena’s preclinical pipeline and expand the use of the biotech’s spreading AAV.SPR ...